research Role of serum androgens and prostate-specific antigen levels in males with androgenetic alopecia
Higher serum androgens contribute to male pattern baldness.
Search
for
Sort by
Research
900-930 / 1000+ resultsresearch Economic Issues in the Treatment of BPH
Combination therapy for BPH is cost-effective, especially for men with larger prostates.
research SAT-288 Successful Virilization of a PAIS Patient with a Missense Mutation In The Ligand-binding Domain Of The Androgen Receptor with Combined High-dose Testosterone and Aromatase Inhibitor
A 12-year-old boy with PAIS successfully developed male characteristics using high-dose testosterone and anastrozole.
research Table_2.docx
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.
research Dynamics of procollagen type 1 N-terminal propeptide in postmenopausal osteoporosis during bisphosphonate therapy and transcranial electrical stimulation
Transcranial electrical stimulation with bisphosphonates helps maintain bone collagen better than bisphosphonates alone.
research Serum Paroxonase 1 Level and Androgenetic Alopecia: Correspondence
PON1 levels might indicate hair loss severity, but other health factors can affect this.
research Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction
Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.
research Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?
PFS and PSSD are similar conditions with persistent sexual dysfunction after stopping medication.
research Virilizing adrenocortical tumor: a case report
The removal of the adrenal tumor improved the patient's symptoms and reduced androgen levels, indicating successful surgery.
research Evaluation Asprosin Level in Polycystic Ovary Syndrome and Its Association with Fetuin a and Some Biochemical Parameter
Fetuin A levels are higher in PCOS patients, while asprosin levels show no difference.
research MP38-07 VASCULAR, NEUROLOGIC AND HORMONAL ABNORMALITIES IN MEN WITH PERSISTENT SEXUAL DYSFUNCTION AFTER DISCONTINUATION OF FINASTERIDE
Men may experience long-term sexual dysfunction after stopping Finasteride.
research Determination of the potency of a novel saw palmetto supercritical CO2 extract (SPSE) for 5α-reductase isoform II inhibition using a cell-free in vitro test system
The new saw palmetto extract effectively inhibits an enzyme linked to prostate enlargement and may be as good as standard treatments.
research Health Utility Measures Among Patients with Androgenetic Alopecia After Hair Transplant
research Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study
High doses of cyproterone acetate are linked to an increased risk of developing meningioma.
research A Slippery Preventive Slope
Finasteride reduces prostate cancer risk but may increase high-grade cancer risk.
research A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia
Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
research Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria
Most women with PCOS have high levels of male hormones, and free testosterone is the best marker for this.
research An (Ir)reversible Affection of the Sexual Sphere: A Case Report
Finasteride can cause long-lasting sexual dysfunction even after stopping the drug.
research Adherence with protocol medication use and mortality from unrelated causes in a prevention trial
Not taking prescribed medications properly can lead to higher death rates from unrelated health conditions.
research Atypical post-finasteride syndrome: A pharmacological riddle
Finasteride and dutasteride can cause severe, lasting side effects.
research 5116 Postmenopausal Hyperandrogenism due to Rare Ovarian Tumor
Rare ovarian tumors can cause hyperandrogenism, even if imaging appears normal.
research Hiperandrogenismo tras la menopausia
A postmenopausal woman's increased male hormone levels were successfully treated with surgery.
research Re: Association of Treatment with 5α-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer
Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.
research Finasteride, To Take, or Not to Take
Finasteride may help prevent prostate cancer, but more research is needed.
research MP-09.08
The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
research Comparison of In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycle Outcome in Patients with and without Polycystic Ovary Syndrome: A Modified Poisson Regression Model.
Women with PCOS have a similar chance of getting pregnant using assisted reproductive treatment as those without PCOS.
research Long-Term Experience With 5-alpha-Reductase Inhibitors.
Finasteride reduces prostate size and symptoms with few side effects.
research The Post-finasteride Syndrome: Clinical Manifestation of Drug-Induced Epigenetics Due to Endocrine Disruption
Finasteride can cause lasting sexual dysfunction, depression, and other side effects, needing more research for treatment.
research PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION
Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
research BPH Medications May Increase Risk of Self-Harm, Depression
BPH medications may increase the risk of self-harm and depression, especially in the first 18 months.